Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDS) in patients with rheumatoid arthritis

Medical Care

Volumn 45, Issue 10 SUPPL. 2, 2007, Pages

  Grijalva, Carlos G ^a   Chung, Cecilia P ^a   Arbogast, Patrick G ^a   Stein, Charles M ^a   Mitchel Jr , Edward F ^a   Griffin, Marie R ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Disease modifying antirheumatic drugs; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT;

AGED; CONFERENCE PAPER; DRUG USE; FEMALE; HUMAN; INSURANCE; MALE; MEDICAID; METHODOLOGY; MIDDLE AGED; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; STATISTICS; SURVIVAL; UNITED STATES;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICAID; MIDDLE AGED; PATIENT COMPLIANCE; PRODUCT SURVEILLANCE, POSTMARKETING; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TENNESSEE;

EID: 34848916744     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/mlr.0b013e318041384c     Document Type: Article

References (53)

1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27:269-281. (Pubitemid 32488705)
2. Wolfe F, Michaud K, Gefeller O, et al. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum. 2003;48:1530-1542. (Pubitemid 36682360)
3. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum. 2002;46:328-346.
4. Williams HJ, Willkens RF, Samuelson CO Jr, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 1985;28:721-730. (Pubitemid 15027325)
5. Hannonen P, Mottonen T, Hakola M, et al. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum. 1993;36:1501-1509. (Pubitemid 23327748)
6. Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum. 1996;39:713-722.
7. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999;159:2542-2550.
8. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-1602.
9. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586-1593. (Pubitemid 32162981)
10. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35-45. (Pubitemid 36091645)
11. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41:2196-2204. (Pubitemid 29009378)
12. Ray WA, Stein CM. Reform of drug regulation - beyond an independent drug-safety board. N Engl J Med. 2006;354:194-201. (Pubitemid 43076719)
13. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum. 2003;48:313-318. (Pubitemid 36277997)
14. Pincus T, Stein CM. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin Exp Rheumatol. 1997;15(suppl 17):S27-S38. (Pubitemid 27346699)
15. Galindo-Rodriguez G, Avina-Zubieta JA, Russell AS, et al. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study. J Rheumatol. 1999;26:2337-2343. (Pubitemid 29528968)
16. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol. 1995;9:619-632.
17. Maetzel A, Wong A, Strand V, et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford). 2000;39:975-981.
18. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497. (Pubitemid 41127293)
19. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565-574. (Pubitemid 44336271)
20. Steiner JF, Earnest MA. The language of medication-taking. Ann Intern Med. 2000;132:926-930. (Pubitemid 30346866)
21. Aletaha D, Stamm T, Kapral T, et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis. 2003;62: 944-951. (Pubitemid 37159492)
22. Hughes DA, Bagust A, Haycox A, et al. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ. 2001;10:601-615. (Pubitemid 32998372)
23. ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet. 1996;347:347-352. (Pubitemid 26046101)
24. Urquhart J. Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens. Pharmacoeconomics. 1999;15: 217-228. (Pubitemid 29133459)
25. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105-116. (Pubitemid 27089212)
26. Berard A, Solomon DH, Avorn J. Patterns of drug use in rheumatoid arthritis. J Rheumatol. 2000;27:1648-1655. (Pubitemid 30462806)
27. Avorn J, Soumerai SB. Use of a computer-based Medicaid drug data to analyze and correct inappropriate medication use. J Med Syst. 1982;4: 377-386. (Pubitemid 13199327)
28. Levy AR, O'Brien BJ, Sellors C, et al. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10:67-71. (Pubitemid 37028596)
29. McKenzie DA, Semradek J, McFarland BH, et al. The validity of medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol. 2000;53:1248-1257. (Pubitemid 32007841)
30. Langman M, Kahler KH, Kong SX, et al. Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol Drug Saf. 2001;10:517-524. (Pubitemid 34100780)
31. Solomon DH, Avorn J, Wang PS, et al. Prescription opioid use among older adults with arthritis or low back pain. Arthritis Rheum. 2006;55:35-41. (Pubitemid 43235125)
32. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-920. (Pubitemid 37323253)
33. Miettinen OS. Stratification by a multivariate confounder score. Am J Epidemiol. 1976;104:609-620. (Pubitemid 8007913)
34. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365:475-481. (Pubitemid 40215729)
35. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin use and the risk of sudden cardiac death. N Engl J Med. 2004;351:1089-1096.
36. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323-337. (Pubitemid 40601980)
37. Kremer JM. Historical overview of the treatment of rheumatoid arthritis with an emphasis on methotrexate. J Rheumatol Suppl. 1996;44:34-37. (Pubitemid 26094645)
38. Weinblatt ME, Maier AL, Fraser PA, et al. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol. 1998;25:238-242. (Pubitemid 28088249)
39. Rich E, Moreland LW, Alarcon GS. Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug. J Rheumatol. 1999;26:259-261. (Pubitemid 29066725)
40. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84:1074-1078.
41. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med. 2006;355:704-712.
42. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004;350:2167-2179.
43. Hyrich KL, Symmons DP, Watson KD, et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006; 54:1786-1794. (Pubitemid 43877928)
44. Zink A, Listing J, Kary S, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis. 2005;64:1274-1279. (Pubitemid 41206242)
45. DeWitt EM, Glick HA, Albert DA, et al. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior. Arch Intern Med. 2006;166:57-63. (Pubitemid 43063842)
46. Wolfe F, Michaud K, Stephenson B, et al. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate. J Rheumatol. 2003;30: 1725-1732. (Pubitemid 36962448)
47. Banthin JS, Miller GE. Trends in prescription drug expenditures by Medicaid enrollees. Med Care. 2006;44(suppl 5):I27-I35. (Pubitemid 43755410)
48. Provider authorization criteria (revised). TennCare Pharmacy Program Documents. Available at: https://tennessee.fhsc.com/Downloads/provider/TNRx- ClinicalEdit-RheumatoidArthritis.pdf.
49. Situnayake RD, McConkey B. Clinical and laboratory effects of prolonged therapy with sulfasalazine, gold or penicillamine: the effects of disease duration on treatment response. J Rheumatol. 1990;17:1268-1273. (Pubitemid 20382849)
50. Anderson JJ, Wells G, Verhoeven AC, et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 2000;43:22-29. (Pubitemid 30368209)
51. Hider SL, Buckley C, Silman AJ, et al. Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. J Rheumatol. 2005;32:11-16. (Pubitemid 40092583)
52. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol. 1990;17:994-1002. (Pubitemid 20278012)
53. Brookhart MA, Wang PS, Solomon DH, et al. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006;17:268-275.